Why the Demands for Pain Management Have Increased in Recent Years
- Aging Population and Chronic Pain: The aging global population continues to be a significant driver of pain management demand. As of 2023, the World Health Organization (WHO) reported that the number of people aged 60 and over has surpassed 1 billion, with many experiencing chronic pain conditions like arthritis and osteoporosis. This demographic trend has created a sustained demand for pain management services and products, especially in countries with rapidly aging populations, such as Japan and Germany.
- Rise in Musculoskeletal Disorders: Musculoskeletal disorders remain a leading cause of disability. According to the Global Burden of Disease Study 2023, low back pain affects nearly 620 million people globally, an increase from previous years. The rise in sedentary lifestyles, poor posture, and obesity have all contributed to the growing prevalence of these conditions, further driving the demand for pain management treatments.
- Post-Pandemic Increase in Chronic Pain: The COVID-19 pandemic has had a lasting impact on global health, including an increase in chronic pain cases. Long COVID, a condition where symptoms persist for months after the initial infection, often includes chronic pain. A 2024 study published in The Lancet found that around 30% of long COVID patients experience chronic pain, contributing to the rising demand for pain management solutions.
- Advancements in Pain Management Therapies: Recent years have seen significant advancements in non-invasive pain management techniques, including the development of new classes of medications, regenerative medicine, and non-opioid therapies. These innovations have expanded treatment options, making pain management more accessible and effective, thus increasing demand.
- Opioid Crisis and Regulatory Changes: The opioid crisis continues to drive a shift towards alternative pain management strategies. The U.S. Centers for Disease Control and Prevention (CDC) reported in 2023 that opioid overdose deaths remained alarmingly high, leading to stricter regulations on opioid prescriptions and an increased emphasis on alternative pain therapies, such as physical therapy, acupuncture, and cognitive-behavioral therapy.
Why the Demands Are Likely to Increase in the Coming Years
- Rising Prevalence of Chronic Diseases: The global burden of chronic diseases like diabetes, cancer, and cardiovascular diseases is expected to continue increasing. According to a 2024 WHO report, chronic diseases are projected to account for 77% of all deaths by 2030. As these conditions often lead to chronic pain, the demand for pain management services is anticipated to grow alongside the rising prevalence of these diseases.
- Technological Advancements: The pain management market is set to benefit from ongoing technological innovations. For instance, in 2024, the FDA approved several new neuromodulation devices for chronic pain treatment, including wearable devices that offer non-invasive pain relief. Additionally, AI-driven pain management platforms are becoming more widespread, offering personalized treatment plans and enhancing patient outcomes.
- Global Healthcare Expansion: Healthcare access is improving in many emerging markets, particularly in Asia-Pacific and Africa. By 2024, several countries in these regions have significantly expanded their healthcare infrastructure, leading to increased availability of pain management treatments. As more people gain access to healthcare services, the demand for pain management is expected to rise, particularly for conditions like cancer-related pain and post-surgical pain.
Top Key Companies in the Pain Management Market with their new technologies and innovations
- Abbott Laboratories
- Neurostimulation Technology: Abbott has made significant advancements in neurostimulation technology for pain management. In 2023, Abbott launched the Proclaim Plus with FlexBurst360™ technology, an enhanced spinal cord stimulation (SCS) system. This system allows for personalized pain relief by targeting pain more precisely, providing patients with better outcomes. Abbott's neuromodulation segment saw a 10% increase in revenue from 2022 to 2023, reflecting strong market adoption.
- Continuous Glucose Monitoring (CGM): Although primarily used for diabetes management, Abbott’s FreeStyle Libre system is increasingly recognized for its role in managing pain associated with diabetic neuropathy. In 2024, Abbott expanded its market share in the CGM market by 15%, with over 5 million users globally.
- Stryker Corporation
- Advanced Surgical Technologies: Stryker continues to innovate in the surgical space, particularly with its Mako Robotic-Arm Assisted Surgery platform, which has revolutionized joint replacement surgeries. This technology improves precision and outcomes, leading to less post-operative pain. In 2023, Stryker’s orthopedic segment, which includes Mako, grew by 8%, driven by increased adoption in hospitals worldwide.
- Spinal Implants and Pain Management: Stryker’s advancements in spinal implants, particularly with the Airo TruCT scanner, offer enhanced imaging for spine surgery, leading to better surgical outcomes and reduced pain. Their spine division saw a 12% increase in revenue in 2023.
- Codman and Shurtleff, Inc. (Part of Integra LifeSciences)
- Neurosurgery Innovations: Codman, under Integra LifeSciences, has focused on developing advanced solutions for neurosurgery. The CereLink® ICP Monitor System, launched in 2023, provides accurate intracranial pressure monitoring, critical in managing patients with traumatic brain injuries where pain management is essential. Codman’s neurosurgical business grew by 9% in 2023, reflecting strong market demand.
- Tissue Regeneration and Repair: Codman is also advancing in tissue regeneration, particularly for neurological applications, which plays a critical role in post-surgical pain management.
- F. Hoffmann-La Roche Ltd
- Personalized Cancer Pain Management: Roche has been a leader in personalized medicine, and their work in oncology has significant implications for pain management. In 2024, Roche launched the Navify® Oncology Hub, an AI-driven platform that helps tailor cancer treatments, including pain management strategies, to individual patients. Roche's oncology segment grew by 11% in 2023, with personalized medicine playing a key role.
- Biopharmaceuticals for Pain Relief: Roche continues to innovate in biopharmaceuticals, with new monoclonal antibodies targeting inflammatory pathways, offering new avenues for pain relief in autoimmune diseases.
- AbbVie (Including Allergan)
- Botox® for Chronic Migraine: AbbVie’s Allergan division continues to dominate the market for Botox® as a treatment for chronic migraine, a significant cause of pain. In 2024, AbbVie reported that Botox® treatments for chronic migraine saw a 7% year-over-year growth, with over 1.6 million treatments administered annually.
- Advanced Immunology Treatments: AbbVie’s Rinvoq® (upadacitinib) and Skyrizi® (risankizumab) are key players in managing pain associated with rheumatoid arthritis and psoriasis. In 2023, sales of these drugs grew by 45% and 51% respectively, driven by their efficacy in reducing pain and inflammation in chronic conditions.
- AstraZeneca plc
- Precision Medicine in Oncology: AstraZeneca’s advancements in precision oncology have also impacted pain management, particularly in reducing cancer-related pain. Their Tagrisso® and Lynparza® therapies, targeting specific genetic mutations in cancer, have seen increased use in 2024, with a reported 12% growth in their oncology portfolio, directly impacting patient pain levels through more targeted treatments.
- Respiratory Treatments: AstraZeneca’s Fasenra® (benralizumab) for severe eosinophilic asthma has helped reduce chronic pain associated with respiratory conditions. In 2023, Fasenra’s sales grew by 18%, reflecting its role in managing chronic respiratory pain.
- Bayer AG
- Non-Opioid Pain Management: Bayer has been focusing on non-opioid pain relief options. Their Aleve® (naproxen sodium) remains a top over-the-counter pain reliever. In 2023, Bayer launched a new extended-release formulation, leading to a 5% increase in sales of Aleve in the U.S.
- Oncology and Pain Relief: Bayer’s Nubeqa® (darolutamide) for prostate cancer, approved in 2022, has shown benefits in pain management for advanced cancer patients. Sales of Nubeqa increased by 40% in 2023, highlighting its growing role in managing cancer-related pain.
- DJO LLC (Part of Colfax Corporation)
- Wearable Pain Management Devices: DJO has been a leader in orthopedic and pain management devices. In 2023, DJO launched the CMF OL1000, a portable bone growth stimulator that uses pulsed electromagnetic fields (PEMF) to promote healing and reduce pain in fractures. DJO’s orthopedic segment saw an 8% increase in revenue in 2023, driven by such innovative devices.
- Enhanced Rehabilitation Solutions: DJO’s MotionMD software, a key innovation for managing patient recovery and pain post-surgery, has seen widespread adoption. This platform saw a 10% increase in user adoption in 2023, reflecting its effectiveness in pain management during rehabilitation.
- Eli Lilly & Company
- Migraine Pain Management: Eli Lilly’s Emgality® (galcanezumab) for migraine prevention continues to be a significant innovation. In 2024, Emgality captured a 25% market share in the migraine prevention market, with sales growing by 20% from 2023. This highlights the growing demand for effective pain management in migraine patients.
- Pain Management for Osteoarthritis: Eli Lilly is also advancing treatments for osteoarthritis. Their drug Tanezumab (an investigational monoclonal antibody for nerve growth factor) has shown promise in late-stage trials, offering a potential new option for managing osteoarthritis pain without opioids.
- Endo Health Solutions
- Targeted Drug Delivery Systems: Endo Health Solutions has focused on targeted drug delivery systems, particularly for post-surgical and chronic pain management. Their Endo Aesthetics division’s Qwo® for cellulite reduction, while cosmetic, also plays a role in managing post-procedural pain. Endo’s sales in this segment grew by 6% in 2023.
- Opioid Alternatives: Endo continues to develop and promote alternatives to traditional opioid therapies. Their Sterile Injectable segment, which includes pain management solutions like Vasostrict® and Adrenalin®, saw a 7% growth in 2023, driven by the demand for safer pain management options.
For more information visit at MarketResearchFuture
Other Trending Reports
